Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Glycopyrronium Bromide in Axillary Hyperhidrosis
NCT03037788Phase 1Completed
- Sponsor
- Dr. August Wolff
- Start
- Nov 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of WO3979 in primary axillary hyperhidrosis (PAH) (4 arms), sponsored by Dr. August Wolff. Primary endpoint: Tolerability and safety assessed through adverse events and local skin reactions at 3 weeks. Started Nov 2016; status: completed.
02
Drugs
WO3979
03
Conditions
primary axillary hyperhidrosis (PAH)
Beyond the preview
Go deeper on NCT03037788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03037788.